Bortezomib and heart failure: Case-report and review of the French Pharmacovigilance database

Fundamental and Clinical Pharmacology

Volumn 28, Issue 3, 2014, Pages 349-352

  Honton, Benjamin ^a,b   Despas, Fabien ^a,b,c   Dumonteil, Nicolas ^a   Rouvellat, Caroline ^a   Roussel, Murielle ^a   Carrie, Didier ^a,b   Galinier, Michel ^a,b   Montastruc, Jean Louis ^a,c   Pathak, Atul ^a,b,c  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b Université de Toulouse   (France)

^c UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Bortezomib; Heart failure; Pharmacovigilance

Indexed keywords

ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; BORTEZOMIB; PYRAZINE DERIVATIVE;

CASE REPORT; CHEMICALLY INDUCED; DRUG DATABASE; DRUG SURVEILLANCE PROGRAM; FRANCE; HEART FAILURE; HEART FUNCTION TEST; HUMAN; MALE; MIDDLE AGED; MULTIPLE MYELOMA; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DATABASES, PHARMACEUTICAL; FRANCE; HEART FAILURE; HEART FUNCTION TESTS; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PHARMACOVIGILANCE; PYRAZINES; TREATMENT OUTCOME;

EID: 84899046075     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/fcp.12039     Document Type: Article

References (11)

1. Barr P., Fisher R., Friedberg J. The role of bortezomib in the treatment of lymphoma. Cancer Invest. (2007) 25 766-775.
2. Bruno B., Rotta M., Giaccone L. et al. New drugs for treatment of multiple myeloma. Lancet Oncol. (2004) 5 430-442.
3. Begaud B., Evreux J.C., Jouglard J., Lagier G. Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie (1985) 40 111-118.
4. Enrico O., Gabriele B., Nadia C. et al. Unexpected cardiotoxicity in haematological bortezomib treated patients. Br. J. Haematol. (2007) 138 396-397.
5. Voortman J., Giaccone G. Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report. BMC Cancer (2006) 6 129.
6. Tang M., Li J., Huang W. et al. Proteasome functional insufficiency activates the calcineurin-NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts. Cardiovasc. Res. (2010) 88 424-433.
7. Carrier L. Too much of a good thing is bad: proteasome inhibition induces stressed hearts to fail. Cardiovasc. Res. (2010) 88 389-390.
8. Hacihanefioglu A., Tarkun P., Gonullu E. Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib. Int. J. Hematol. (2008) 88 219-222.
9. Bockorny M., Chakravarty S., Schulman P., Bockorny B., Bona R. Severe heart failure after bortezomib treatment in a patient with multiple myeloma: a case report and review of the literature. Acta Haematol. (2012) 128 244-247.
10. Goldstein D.B., Need A.C., Singh R., Sisodiya S.M. Potential genetic causes of heterogeneity of treatment effects. Am. J. Med. (2007) 120 S21-S25.
11. Patterson C., Ike C., Willis P.W., Stouffer G.A., Willis M.S. The bitter end: the ubiquitin-proteasome system and cardiac dysfunction. Circulation (2007) 115 1456-1463.